Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
about
Marked increases in mucociliary clearance produced by synergistic secretory agonists or inhibition of the epithelial sodium channel.Effects of secretagogues on net and unidirectional liquid fluxes across porcine bronchial airways.New horizons in the treatment of cystic fibrosis.Novel small molecule epithelial sodium channel inhibitors as potential therapeutics in cystic fibrosis - a patent evaluation.Measurement of the airway surface liquid volume with simple light refraction microscopy.Duration of action of hypertonic saline on mucociliary clearance in the normal lungENaCs and ASICs as therapeutic targets.Inhibition of airway surface fluid absorption by cholinergic stimulationQuercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: therapeutic implications for chronic rhinosinusitisRegulation of the epithelial Na+ channel by peptidases.The epithelial sodium channel mediates the directionality of galvanotaxis in human keratinocytes.Fluorescent aminoglycosides reveal intracellular trafficking routes in mechanosensory hair cells.Airway drug pharmacokinetics via analysis of exhaled breath condensate.Regulation of the epithelial Na+ channel and airway surface liquid volume by serine proteases.Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Gaining the Upper Hand on Pulmonary Drug Delivery.Epithelial Sodium Channel ENaC is a Modifier of the Long Term Non-progressive Phenotype Associated with F508del CFTR Mutations.SPX-101 is a Novel ENaC-targeted Therapeutic for Cystic Fibrosis that Restores Mucus Transport.The function and regulation of acid-sensing ion channels (ASICs) and the epithelial Na(+) channel (ENaC): IUPHAR Review 19.CNS sites activated by renal pelvic epithelial sodium channels (ENaCs) in response to hypertonic saline in awake rats.Evaluating the Functionality of Conjunctiva Using a Rabbit Dry Eye Model.The epithelial Na+ channel is inhibited by a peptide derived from proteolytic processing of its alpha subunit.Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia.The guinea-pig tracheal potential difference as an in vivo model for the study of epithelial sodium channel function in the airways.AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells.Hypertonic saline therapy in cystic fibrosis: Evidence against the proposed mechanism involving aquaporins.Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis.Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice.ENaC proteins are required for NGF-induced neurite growth.Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands.Nasospheroids permit measurements of CFTR-dependent fluid transport.Nonclinical safety assessment of SPX-101, a novel peptide promoter of epithelial sodium channel internalization for the treatment of cystic fibrosis.Evaluation of a SPLUNC1-derived peptide for the treatment of cystic fibrosis lung disease.Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung.Recent advances in developing therapeutics for cystic fibrosisEmerging drug treatments for cystic fibrosis
P2860
Q30828169-CFD9792A-B4B7-4CAA-8CC4-247B61A06CEEQ33655912-253234AD-D00B-4B8C-BE7E-AF1783C69696Q33756002-E09BFDA9-F6DF-4D9C-9041-04CE67836261Q34955473-852561E8-7614-40A9-BCDA-ACA34A9C9D8DQ35219853-0F0A517D-B2B4-4D0D-8DE0-DB658B056CD6Q35749773-473C84B3-6E7B-4560-BCFD-44400DBF8B7DQ35900722-4A46544F-876A-43F0-90EE-A2CA81296F38Q36548925-6893CD8B-D11E-4313-A36F-8D93D24337AEQ36644937-FF032D52-9B2F-416C-ABDF-88E261301CBBQ36752268-29CBE2C3-F60B-477E-928E-9A1A1E2E973CQ36882853-CB976070-882D-41DA-9295-750810C9CD99Q37610685-219DD04D-A9A9-489C-86E5-332857E8FE53Q37625778-9E81AF99-A8ED-4F1E-8737-548A07517828Q37733388-5184F617-D258-42CD-B32A-EE33CF03CFACQ38113749-609F2340-16AA-4B65-AB13-FD68C29DA169Q38240156-96544260-E6E1-4480-AE25-E096CF77A130Q38679109-6F66B565-E22B-4F2A-B4AB-6C1A1FF1C1EEQ38798339-12AB6F8C-36D7-4716-A9C3-9194A71C9050Q38859500-51051B53-3281-4136-AE36-B67BAF1D730BQ38975401-5951B592-D0F3-4043-B90A-753848D956AEQ39816145-48577843-76FD-4472-82DB-937413EA015CQ40281076-6B74B21F-6460-4A45-B10A-6EB80CB33D23Q40829135-7F1F5A34-916E-464C-9246-5DACD7A6EBB2Q40920604-18E7BCFC-7E95-42A2-B599-C37290CB45EFQ41139356-4A8B5136-137A-4A90-B2EE-7216EC46D273Q41419182-8A10747F-23B8-4159-A2F4-621B33E1EBCEQ42497993-978B761A-3983-4D9A-863E-F39D8AB60993Q44313526-B823DD61-DB64-4B6D-8D40-ABF65E7394F6Q46320247-AC133843-B57C-4315-8F60-6D161FA38096Q46726601-9004606C-3434-4C0E-BEEC-918EE2FC4913Q46892762-3B312EEA-EDB2-49B2-A8BD-853F8802A64AQ47657423-62C9C844-DECD-443E-B9FF-8A396A0D9ACFQ47752040-E2B52548-53F0-47C3-9169-C725AE2D9B40Q47855609-B36AFC8F-5485-4043-946C-AA81B36728B8Q54215071-101BD48D-C02A-4EB7-81B8-185CFF0D9F34Q57172314-2FE6F45F-2B50-4262-9AC3-6CC6E625749EQ57952080-61FC738C-9611-4677-B511-593D9E2228DA
P2860
Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Evaluation of second generatio ...... cystic fibrosis lung disease.
@ast
Evaluation of second generatio ...... cystic fibrosis lung disease.
@en
Evaluation of second generatio ...... cystic fibrosis lung disease.
@nl
type
label
Evaluation of second generatio ...... cystic fibrosis lung disease.
@ast
Evaluation of second generatio ...... cystic fibrosis lung disease.
@en
Evaluation of second generatio ...... cystic fibrosis lung disease.
@nl
prefLabel
Evaluation of second generatio ...... cystic fibrosis lung disease.
@ast
Evaluation of second generatio ...... cystic fibrosis lung disease.
@en
Evaluation of second generatio ...... cystic fibrosis lung disease.
@nl
P2093
P356
P1476
Evaluation of second generatio ...... cystic fibrosis lung disease.
@en
P2093
Andra Zamurs
Andrew J Hirsh
Anthony M Paradiso
Juan R Sabater
Richard C Boucher
Rick T Smith
Sam Hopkins
William M Abraham
P304
P356
10.1124/JPET.104.071886
P407
P577
2004-07-23T00:00:00Z